Background {#Sec1}
==========

The *SLC29A3* gene, also called ENT3 (equilibrative nucleoside transporter 3), encodes a nucleoside transporter protein. The ENT3 protein is found in intracellular membranes, especially in lysosomal and mitochondrial membranes \[[@CR1], [@CR2]\]. Because of wide spread biochemical roles of nucleoside molecules, any disruption in metabolism and trafficking of nucleosides could result in various abnormal phenotypes.

Based on the literatures, the mutations in the *SLC29A3* gene cause a wide range of different clinical manifestations including H syndrome (defined by cardiac anomalies, camptodactyly, short stature, hypergonadotropic hypogonadism, hepatosplenomegaly, scrotal masses, growth retardation, and sensorineural hearing loss \[[@CR3]--[@CR7]\]), pigmented hypertrichosis with insulin dependent diabetes (PHID) (characterized by hyperpigmented and hypertrichotic skin, hepatosplenomegaly, hypogonadism, diabetes mellitus, comptodactyly, clinodactyly, chronic inflammatory syndrome, and growth retardation \[[@CR8]\]), Faisalabad histiocytosis (FHC) (defined by deafness, growth retardation, hypogonadism, camptodactyly, and Rosai Dorfman disease \[[@CR9], [@CR10]\]), and dysosteosclerosis (DSS) \[[@CR8], [@CR11], [@CR12]\] (characterized by hyperpigmented skin, frontal bossing, mid-face hypoplasia, short stature, sclerotic platyspondyly, otosclerosis, and compression of CNS and cranial nerves \[[@CR11]\]). However, it is worth mentioning that all these disorders, with their different names and terminologies, are actually the same entity termed H syndrome. For this reason, their description as different entities is misleading. As outlined above, a number of phenotypes including patches and plaques of hyperpigmented and hypertrichotic skin, short stature, camptodactyly, hearing problems, myelofibrosis, hepatosplenomegaly, pulmonary stenosis, pericarditis, diabetes, and hypogonadism \[[@CR7], [@CR11], [@CR13]\] are common among H syndrome affected patients but not all phenotypes are seen in all patients. In this report, we describe a novel homozygous frame-shift mutation in *SLC29A3* gene and its related phenotypes in two Iranian related families.

Case presentation {#Sec2}
=================

The studied families are of Iranian origin located in Semnan province (central Iran). As shown in Fig. [1](#Fig1){ref-type="fig"}, four affected individuals are included in two related families (a brother and a sister from each family), with two common ancestors. All four patients were born at term, with normal health indicators and metrics, following an uneventful pregnancy. Their ages ranged between 35 and 46 years. The clinical and demographic data of the patients are summarized in Table [1](#Tab1){ref-type="table"}. In addition, camptodactyly phenotype in patient III-5 is depicted in Fig. [2](#Fig2){ref-type="fig"}. Fig. 1Pedigree and segregation analysis of the SLC29A3 gene mutation (c.307-308delTT). All four patients (III.2, III.5, III.8, and III.11) are homozygote mutants, whereas parents of proband (II.1 and II.2) are heterozygote. Furthermore, sequence analysis of the three normal siblings of the patients in two families revealed that two of them (III.1 and III.6) are heterozygote and one (III-9) is normal Table 1Summary of clinical and demographic findingsFamily 1Family 2Patient III-2Patient III-5Patient III-8Patient III-11^a^SexFemaleMaleFemaleMaleAge (years)46353741Height (cm)170178167180Age of onset (years)^b^1567--85Hearing lossMildProfoundProfoundProfoundCamptodactyly++++ESR (mm/h)70--11045No dataNo dataPolyclonal gammopathySevereMildMild--Skin changesNoNoNoNoIDDM----++Arthropathy++++Delayed pubertyYesYesNoNoCRP mg/dL30--9034No dataNo dataRheumatoid arthritis++++Lymph nodesGeneralized LymphoadenopathyNoNoNo*ESR* erythrocyte sedimentation rate, *IDDM*  Insulin dependent diabetes mellitus, *CRP* C reactive protein^a^ The patient III-11 died due to the diabetes^b^ For clinical manifestations Fig. 2The hands and feet of patient III.5 which show camptodactyly phenotype

After obtaining informed consent, the peripheral blood samples were collected from patients and their family members. Genomic DNA was extracted from blood samples by QIAamp DNA Blood Mini Kit (Germany) according to the manufacturer's instructions. At first, the patients were investigated for mutations of *GJB2* gene using ASPCR (Allele Specific PCR) and sequencing followed by screening of two known deletions del(D13S1830) and del(D13S1854) of *GJB6* gene. Since the studied patients were negative for *GJB2* and *GJB6* genes mutations, the patient III-5 was more investigated by Next Generation Sequencing. For this purpose, Whole Exome Sequencing (WES) was used to enrich all exons of protein-coding genes as well as some other important genomic regions. The WES was performed to sequence close to 100 million reads on Illumina HiSeq2000 Sequencer. Generally, the test platform examined \> 95% of the targeted regions with sensitivity of above 99%. In this test, point mutations and micro-insertions/deletions as well as duplications (\< 20 bp) can be simultaneously detected. Analysis of the sequencing results was performed using BWA aligner \[[@CR14]\], annovar \[[@CR15]\] and GATK \[[@CR16]\] open access software as well as public databases ExAC, gnomAD, Kaviar (\~Known VARiants) and GME. Additionally, ACMG guidelines and local population database with more than 1500 unrelated individuals (BayanGene) were used. Standard bioinformatics tools used were as follows: CADD_phred, REVEL, MCAP, SIFT, Polyphen, LRT, MutationTaster, and MutationAssessor. Furthermore, to confirm the novel mutation found in the *SLC29A3* gene, PCR and sequencing were performed for patients and their normal family members using following primers: F-5′ CAGTCCATGGGCAGAAGTGT 3′ and R- 5′ TCGCCTACCTGTTGACAAGC 3′ (PCR product: 401 bp). Finally, the Sanger sequencing data was analyzed by Chromas software.

Based on the results, all four analyzed patients were negative for *GJB2* mutations and two common large deletions of *GJB6* gene. Subsequently, the NGS analysis of proband (patient III-5) revealed one deleterious homozygous mutation in *SLC29A3* gene. This homozygous deletion includes two thymidine nucleotides (c.307-308delTT) of exon 3 causing a frame-shift mutation that immediately, makes a stop codon (TGA) instead of Phe103 codon (TTT) (*SLC29A3*:NM_001174098:exon3:c.307-308delTT:p.Phe103fs) (Fig. [3](#Fig3){ref-type="fig"}). The mutation found, validated by Sanger sequencing. Fig. 3Schematic illustration for loss of 10 out of 11 transmembrane domains of ENT3 protein as a consequence of c.307-308delTT (p.Phen103fs) frame-shift mutation in *SLC29A3* gene. **a** The normal sequence of the gene and the corresponding amino acid sequence have shown on the left. Two deleted thymidines are underlined. The mutated sequence and the corresponding truncated protein are depicted on the right. **b** Ten out of 11 transmembrane domains of ENT3 protein are deleted due to frame-shift mutation c.307-308delTT (p.Phen103fs)

At the next step, segregation analysis of novel homozygous mutation found was performed for other family members including another three patients (patients III-2, III-8, and III-11). As expected, parents of proband were heterozygote for reported mutation. A similar result was achieved from the parents of patient III-8 (data not shown). Furthermore, the obtained results showed that patients III-2, III-8, and III-11 have the found deleterious mutation. Furthermore, three normal siblings of the patients were also checked for the deleterious mutation 307-308delTT of *SLC29A3* gene. The results clearly revealed that two of them (III-1 and III-6) are heterozygote and one (III-9) is normal homozygote. The corresponding family pedigree with the results of sequence analyses are illustrated in Fig. [1](#Fig1){ref-type="fig"}.

Discussion and conclusion {#Sec3}
=========================

As previously mentioned, the mutation in *SLC29A3* gene causes a wide range of mild to severe different medical manifestations which are known as the same entity termed H syndrome. To date, more than 22 pathogenic or likely pathogenic mutations have been reported in the *SLC29A3* gene (Table [2](#Tab2){ref-type="table"}). As shown in Table [2](#Tab2){ref-type="table"}, the preliminary report for 308-309delTT (OMIM: 612373.0009) frame-shift mutation, which is resulted in truncated protein has been published in 2010 \[[@CR10]\]. However, they found a heterozygous form of this mutation in combination with heterozygous missense mutation Gly437Arg as compound heterozygote, which is led to H syndrome. Here, we have explained the first report of novel homozygous form of this deleterious mutation from two Iranian related families. All four reported patients were results of consanguineous marriages. As previously pointed out, this frame-shift mutation is resulted in premature protein truncation. The truncated ENT3 protein loses its 10 out of 11 transmembrane domains (Fig. [3](#Fig3){ref-type="fig"}). Therefore, it seems that this homozygous mutation, as a loss of function mutation, leads to elimination of ENT3 protein function. Table 2A summary of the reported pathogenic/likely pathogenic mutations of *SLC29A3* geneNucleotide changeGenotypeConsequence(Clinical significance) Main PhenotypesFamily originReference/ (variation ID in ClinVar)c.243delAHomop.Lys81AsnfsPathogenicNasal infiltration, Pancreatic exocrine deficiency, Insulin-dependent diabetes, Contractures of the fingers, Contractures of the toes, Retroperitoneal fibrosisMoroccan\[[@CR17]\]c.308-309delTTHeterop.Phe103Terfs(Pathogenic)Histiocytosis, Rosai-Dorfman diseaseTurkish and Palestinian\[[@CR10]\]c.300 + 1G \> A (IVS2 + 1G \> A)^a^HomoSplice sitePakistanic.73C \> T--p.Arg25Ter(Likely pathogenic)Histiocytosis-lymphadenopathy plus syndrome--(ID: 212200)c.300 + 1G \> C--Splice site(Pathogenic)not provided(ID: 427021)c.347 T \> GHomop.Met116Arg(Pathogenic)insulin-dependent diabetes mellitus and pigmented hypertrichotic skin lesionsAustralian Lebanese\[[@CR8]\]c.940delTp.Tyr314ThrfsTer91Indianc.1309G \> Ap.Gly437ArgPakistanic.1330G \> Tp.Glu444TerNorth American Caucasianc.1346C \> Gp.Thr449ArgAustralian Lebanesec.479G \> A--p.Trp160Ter(Pathogenic)Histiocytosis-lymphadenopathy plus syndrome--(ID: 573984)c.607 T \> CHeterop.Ser203Pro(Pathogenic)Dysosteosclerosis--\[[@CR11]\]c.1157G \> Ap.Arg386Glnc.1346C \> GHomop.Thr449Argc.714_715invTG--p.Val239Ile(Likely pathogenic)Histiocytosis-lymphadenopathy plus syndrome--(ID: 300363)c.1001A \> G--p.Asn334Ser(Likely pathogenic)Histiocytosis-lymphadenopathy plus syndrome--(ID: 300368)c.1045delCHomop.Leu349Serfs(Pathogenic)Hyperpigmentation, Fixed flexion contractures of proximal interphalangeal joints, Hallux valgus, Prominent gynecomastia, histiocytic and dendritic infiltrateBulgarian\[[@CR18]\]c.1087C \> Tp.Arg363TrpSpanish\[[@CR4]\]c.1088G \> Ap.Arg363GlnArabc.1228C \> T--p.Gln410Ter(Pathogenic)Histiocytosis-lymphadenopathy plus syndrome--(ID: 130338)c.1279G \> AHeterop.Gly427Ser(Pathogenic)seronegative polyarthritis, hypogonadotropic hypogonadism, hearingloss, Proptosis, Arthropathy, Camptodactyly, Delayed puberty, Polyclonal gammopathyArab\[[@CR7]\]c.307-308delTTHomop.Phe103Terfs(Pathogenic)Hearing loss, Camptodactyly, Polyclonal gammopathy, Arthropathy, Delayed puberty, Rheumatoid arthritisIranianThis report^a^*IVS* InterVening Sequence (i.e. an intron)

As shown in Table [1](#Tab1){ref-type="table"}, some of the common manifestations have been seen in our patients. Nonetheless, some of the phenotypes have not seen or were different among patients of two studied families. For example, although the short stature is reported in mostly reports for H syndrome \[[@CR7], [@CR11], [@CR13]\], all four patients in this report have normal height (167--180 cm), in accordance with two previously reported cases from Morocco \[[@CR17]\]. Similarly, and in accordance with some reports \[[@CR8], [@CR12]\], all patients in this study have moderate (patient III-2) to profound deafness (patients III-5, III-8, and III-11). Deafness has also been reported in other previous reports \[[@CR4], [@CR18]\], which is in accordance with our observations. Although these reported patients showed other manifestations including, hyperpigmentation, hypertrichosis, fixed flexion contractures of proximal interphalangeal joints, Hallux valgus and fixed flexion contractures of toe joints. However, the hearing loss has not been reported in originally reported PHID (other form of H syndrome) patients \[[@CR19], [@CR20]\]. Delayed puberty was observed in patients of family 1 (Patients III-2 and III-5). This observation is in line with those reported by Cliffe et al. (2009) and Hussain et al. (2009) \[[@CR8], [@CR19]\].

In accordance with other reports \[[@CR7], [@CR11]\], all four studied patients were suffered from camptodactyly. While the normal ESR range is 0--22 mm/h for men and 0--29 mm/h for women, a high ESR was observed in two patients III-2 and III-5. On the other words, it seems that the high levels of CRP in patients III-2 and III-5 could because of rheumatoid arthritis in these patients (normal CRP level is below 3.0 mg/L). Although, there was no data for ESR and CRP levels of patients III-8 and III-11, clinical symptoms of the rheumatoid arthritis were also confirmed by a rheumatologist in these patients. This result is in agreement with clinical symptoms of a previously reported patient \[[@CR7]\]. While, the severe polyclonal gammopathy was observed in patient III-2, a mild representation was observed in patients III-5 and III-8 indicating variable expressivity of mutant *SLC29A3* gene. Polyclonal gammopathy could be due to the elevated production of immunoglobulins by plasma cells \[[@CR21]\]. Unlike the monoclonal gammopathy, polyclonal gammopathy is associated with a nonmalignant condition. In the present study, patient III-2 has been shown generalized lymphadenopathy. This observation is similar to previously reported lymphadenopathy in mutated *SLC29A3* patients \[[@CR5], [@CR7], [@CR8], [@CR10], [@CR11], [@CR20]\]. Corresponding to the previously report from Morocco \[[@CR17]\], despite the hyperpigmented/hypertrichotic skin is the common feature in *SLC29A3* mutants \[[@CR11]\], none of the patients reported in this paper have skin changes. Similarly, although mutation in *SLC29A3* gene mostly leads to diabetes \[[@CR7], [@CR11], [@CR22]\], we observed this phenotype only in the patients of the family 2 (patients III-8 and III-11) showing the variable expressivity and eventually involvement of other genes. Similar observation has been conducted by Spiegel et al. (2010) \[[@CR7]\]. All four patients were suffered from arthropathy and rheumatoid arthritis. This is in accordance with several previously reported cases \[[@CR7], [@CR23]\].

In conclusion, this report shows that a homozygous frame-shift mutation c.307-308delTT results in a complex of clinical manifestations of H syndrome. In addition to allelic heterogeneity, it seems that these various clinical symptoms clearly confirm the pleiotropic effects and variable expressivity of *SLC29A3* gene as well as possible involvement of other genes. On the other words, the obtained results showed that whole-exome sequencing is a useful method discovering genes involved in human genetic diseases.
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